Your session is about to expire
What is Inqovi
Effectiveness
When to interrupt dosage
The proposed dosage of Inqovi is contingent upon the acknowledged condition, including Chronic Myelomonocytic Leukemia, Anemia and Refractory anemias. Dosage is also determined by the delivery technique (e.g. Intravenous or Injection, powder, for solution) specified in the table beneath.Warnings
There are 20 known major drug interactions with Inqovi.Inqovi Novel Uses: Which Conditions Have a Clinical Trial Featuring Inqovi?
183 active clinical trials are being conducted to assess the efficacy of Inqovi in alleviating Anemia, Refractory Anemia and Myelodysplastic Syndrome.Inqovi Reviews: What are patients saying about Inqovi?
Patient Q&A Section about inqovi
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.Is Inqovi chemotherapy?
"Inqovi is a new drug that pairs decitabine with cedazuridine. Decitabine is an established anti-cancer drug, but it is not effective when taken orally because it is broken down by an enzyme called cytidine deaminase. Cedazuridine inhibits this enzyme, making it possible for decitabine to be taken orally."
How long does it take for Inqovi to work?
"You may not see the effects of INQOVI for 4 or more cycles. Your blood cell counts may change within the first 2 months. Your healthcare provider will take blood tests before you start treatment with INQOVI and again before each 28-day cycle to check how well the treatment is working."
What is Inqovi used for?
"INQOVI is a medication used to treat adults with myelodysplastic syndromes, including chronic myelomonocytic leukemia. Myelodysplastic syndrome is a type of blood cancer in which blood cells in the bone marrow are defective, leading to a low number of one or more types of blood cells."